ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 1 filers reported holding ASCENDIS PHARMA A/S in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,458,518 | -13.8% | 26,255 | -17.8% | 1.74% | -1.9% |
Q2 2023 | $2,851,538 | -5.5% | 31,950 | +13.5% | 1.77% | -9.2% |
Q1 2023 | $3,018,243 | -19.1% | 28,150 | -53.9% | 1.95% | -41.2% |
Q4 2022 | $3,731,135 | +42.2% | 61,040 | +140.2% | 3.31% | -0.5% |
Q3 2022 | $2,624,000 | +11.1% | 25,410 | 0.0% | 3.33% | +48.3% |
Q2 2022 | $2,362,000 | -18.9% | 25,410 | +2.4% | 2.24% | -16.3% |
Q1 2022 | $2,912,000 | -9.2% | 24,810 | +4.1% | 2.68% | +20.9% |
Q4 2021 | $3,207,000 | +1.1% | 23,840 | +19.7% | 2.22% | +89.7% |
Q3 2021 | $3,173,000 | +26.4% | 19,910 | +4.3% | 1.17% | +47.1% |
Q2 2021 | $2,511,000 | -51.7% | 19,090 | -52.7% | 0.79% | +5.9% |
Q1 2021 | $5,204,000 | +78.8% | 40,380 | +131.3% | 0.75% | -17.0% |
Q4 2020 | $2,911,000 | +16.7% | 17,460 | +8.0% | 0.90% | -9.5% |
Q3 2020 | $2,494,000 | +23.5% | 16,160 | +18.3% | 1.00% | +48.9% |
Q2 2020 | $2,020,000 | +47.6% | 13,660 | +12.3% | 0.67% | +24.5% |
Q1 2020 | $1,369,000 | -10.2% | 12,160 | +10.9% | 0.54% | -50.1% |
Q4 2019 | $1,525,000 | +50.4% | 10,960 | +4.1% | 1.08% | -13.2% |
Q3 2019 | $1,014,000 | -12.2% | 10,530 | +5.0% | 1.25% | -15.4% |
Q2 2019 | $1,155,000 | -3.1% | 10,030 | -1.0% | 1.47% | +2.3% |
Q1 2019 | $1,192,000 | +182.5% | 10,130 | +50.5% | 1.44% | +171.0% |
Q4 2018 | $422,000 | -47.4% | 6,730 | -40.6% | 0.53% | -26.4% |
Q3 2018 | $803,000 | -15.6% | 11,330 | -20.8% | 0.72% | -4.1% |
Q2 2018 | $951,000 | +59.8% | 14,300 | +57.1% | 0.75% | +108.3% |
Q1 2018 | $595,000 | +22.9% | 9,100 | -24.7% | 0.36% | +63.3% |
Q4 2017 | $484,000 | +55.6% | 12,090 | +40.7% | 0.22% | +49.3% |
Q3 2017 | $311,000 | +30.7% | 8,590 | 0.0% | 0.15% | +22.3% |
Q2 2017 | $238,000 | – | 8,590 | – | 0.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |